ASPIrin in Reducing Events in Dialysis ( ASPIRED )

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 9082 participants.

Also called NCT04381143

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 9,082 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04381143
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04381143. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-30 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
Condition
CKD (Chronic Kidney Disease) Stage 5D
Intervention (Drug)
Aspirin 100 mg Oral Tablet
Intervention (Drug)
Matching Placebo
Lead sponsor
Guangdong Provincial People's Hospital (class: other)
Collaborator
The George Institute (class: other)

Record details

Record id
cardio:ct-nct04381143
Content hash
3dd177f63ad937b63501de7e6f6ff25e56007973b4aa36d8f216cf0b39341911